Cell2Cure can produce, store and distribute stem cells from healthy donors. So far, Cell2Cure produces stem cells on a smaller scale for clinical trials in humans and laboratory use, but the technology has the potential to be scaled for industrial commercial production.
Danish phase I and preliminary national and international phase II studies have shown, that Cell2Cure stem cells are safe, useful and have promising clinical effects on cardiac patients. In the clinical studies for patients with cardiovascular disease and heart failure, it has validated that after treatment with stem cells, patients have improved both their heart pump function and quality of life.
Now, an InnoBooster project provides the innovative power to make it possible to bring Cell2Cure’s donor stem cells to the market on a large scale.
The use of healthy donor stem cells overcomes several of the barriers to stem cell therapy for the benefit of patients. The challenge of using patients’ own stem cells is that it logistically, as well as financially, requires considerable resources. Today, it takes up to 6-8 weeks to grow enough stem cells to treat just one patient.
With Cell2Cure technology, it becomes possible to go from small individual patient productions of stem cells to large-scale production of ready-to-use products, which can be delivered immediately in reproducible and sufficient quantities.
The team behind Cell2Cure has expertise in stem cells, clinical development, heart disease and drug development. On the research side, Cell2Cure works closely with the Cardiology Stem Cell Center at Rigshospitalet – one of the world leaders in growing stem cells from healthy donors and the driving force in several national and international trials with stem cells from healthy donors.